ELI
ACAD icon

Empire Life Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Empire Life Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-160,662
Closed -$2.61M – 97
2024
Q2 		$2.61M Sell
160,662
-9,173
-5% -$148K 0.16% 70
2024
Q1 		$3.14M Sell
169,835
-4,980
-3% -$123K 0.19% 64
2023
Q4 		$5.47M Buy
174,815
+467
+0.3% +$11.2K 0.35% 59
2023
Q3 		$3.63M Sell
174,348
-2,714
-2% -$73.7K 0.27% 60
2023
Q2 		$4.24M Sell
177,062
-461
-0.3% -$10.2K 0.29% 59
2023
Q1 		$3.34M Buy
177,523
+1,682
+1% +$32K 0.24% 62
2022
Q4 		$2.8M Sell
175,841
-2,011
-1% -$31.4K 0.19% 65
2022
Q3 		$2.91M Buy
177,852
+5,930
+3% +$96K 0.22% 64
2022
Q2 		$2.42M Buy
171,922
+3,301
+2% +$61.6K 0.17% 65
2022
Q1 		$4.08M Buy
168,621
+345
+0.2% +$8.35K 0.26% 64
2021
Q4 		$3.93M Buy
168,276
+323
+0.2% +$6.5K 0.24% 66
2021
Q3 		$2.79M Buy
167,953
+1,988
+1% +$38.3K 0.18% 69
2021
Q2 		$4.05M Buy
165,965
+5,147
+3% +$116K 0.26% 67
2021
Q1 		$4.15M Buy
160,818
+107,772
+203% +$4.74M 0.29% 68
2020
Q4 		$2.84M Buy
53,046
+22,520
+74% +$1.12M 0.2% 74
2020
Q3 		$1.26M Buy
+30,526
New +$1.32M 0.1% 79

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Empire Life Investments's ACAD Position: Q3 2024 in Review

Empire Life Investments sold out of Acadia Pharmaceuticals (ACAD) in Q3 2024, closing a stake of 160,662 shares — an estimated $2.61M sold.

Empire Life Investments first reported a position in ACAD in Q3 2020 and held it in 16 quarters. The position peaked at $5.47M in Q4 2023. 256 funds tracked by Wall St. Rank hold ACAD as of Q3 2024.

  • Empire Life Investments reported no remaining Acadia Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Empire Life Investments sold 160,662 Acadia Pharmaceuticals shares in Q3 2024, an estimated $2.61M.
  • Empire Life Investments first reported a position in Acadia Pharmaceuticals in Q3 2020 and held it in 16 quarters.
  • Empire Life Investments's Acadia Pharmaceuticals position peaked at $5.47M in Q4 2023.
  • 256 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2024.

Based on Empire Life Investments's 13F filing for Q3 2024, filed 29 Oct 2024.